uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. - Wikidata - awgldk - TriplyDB

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

http://www.wikidata.org/entity/Q35720929

about

Circulating tumor cells in breast cancer: a tool whose time has come of age uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180.Detection of circulating tumor cells Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer Computer aided identification of small molecules disrupting uPAR/alpha5beta1--integrin interaction: a new paradigm for metastasis prevention Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines Mesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential.Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients Circulating tumor cell analysis: technical and statistical considerations for application to the clinic.The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients uPAR and HER2 Genes Are Usually Co-Amplified in Individual Breast Cancer Cells from Blood and Tissues.All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer.Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer.SELEX aptamer used as a probe to detect circulating tumor cells in peripheral blood of pancreatic cancer patients.A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?Clinical relevance and biology of circulating tumor cells.Molecular profiling of individual tumor cells by hyperspectral microscopic imaging A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation The Role of Regulatory B Cell-Like Malignant Cells and Treg Cells in the Mouse Model of BCL1 Tumor Dormancy.Considerations in the development of circulating tumor cell technology for clinical use Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status In Vivo Monitoring of Multiple Circulating Cell Populations Using Two-photon Flow Cytometry.Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer Models, mechanisms and clinical evidence for cancer dormancy.Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application?The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients.3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer.The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.Versatile immunomagnetic nanocarrier platform for capturing cancer cells.Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer.High concentration of urokinase-type plasminogen activator receptor in the serum of women with primary breast cancer.Circulating tumor cells as prognostic marker in metastatic breast cancer.

P2860

Q21245253-777B6584-5197-4389-9027-795C047D0920 Q24642555-5D9AC5A3-029B-466F-A510-164F44299231 Q26859334-7AEE45A6-38D4-4652-9431-A69E4802FA62 Q28066285-CCFB1B1C-7CE9-457A-83DA-9881590D755D Q28085413-13E2606A-0B4C-442B-9BCB-6C8DBE53CE2E Q28474854-C0C5E22D-0556-4DA9-852D-748A9D55B78E Q28483475-E9C043FF-3DF2-4FF9-8431-FEADC63FCBB0 Q31158116-51CD99A5-CC30-40D6-83C2-4A6077A26FA2 Q33555492-D0687CDC-5FC6-472E-B931-7E5B595E4FE2 Q33559406-766B16F8-9D4A-43EC-A37E-937A3833D20E Q33649574-4303E329-53CF-446E-B222-1509AF2A39E9 Q33723658-32CB0750-F79B-4FA1-BCF1-AE2B26C90203 Q34095775-F00EA51E-9326-430B-A65D-341BA49E5DA2 Q34098110-409224CC-E906-447F-AC38-48A34840DFCA Q34796583-507761DF-AA18-41C3-81E7-8992575E9DF0 Q35208647-D247B049-B5CA-467B-846F-1F95DAFA1E76 Q35538013-385003AC-36D1-4493-9888-A1B3A4F1C206 Q35768425-3C3ACB05-A2B0-40A1-875C-35A63DAFF905 Q35889548-3B151C60-9E26-4801-9004-9D435CBF681F Q35913941-73E40B0A-BB49-42DA-91E6-DE91BD528702 Q36059078-1F7F5A0E-2F63-4642-B3F2-8D843497CCD6 Q36206190-630B7697-CAE8-4FE8-B252-23C92076F937 Q36222003-05107798-8288-4C94-885F-64DE35EAAB88 Q36338628-F4BAE9C7-C160-416E-B519-B7457239F332 Q36458793-D9455577-10EF-4017-A7D2-4D5902B100AC Q36600378-0A7695C5-F670-414A-9FDF-E250C5DCD188 Q36745487-353002C4-A23D-49BC-837F-E63FB5642C70 Q36844303-239E8751-03B8-43D7-AEA2-273594ED20F9 Q36955133-7A279F3D-3EEC-493B-8B23-1953A259C925 Q36974719-E4C3F1D9-A6DC-4DDB-85D2-D9E0D9E8E989 Q36997621-FBF280D0-B959-4845-9E95-C96C435086A9 Q37019257-39DD78E5-E36C-4DA3-B082-FC31A97E3553 Q37038635-425A5C6E-2069-48A7-BB63-D6BF5E2D3228 Q37259934-86CA603A-7A27-4BA3-BEC5-5E9DF257E6E0 Q37277185-5439F51F-C44B-4C75-AF87-41AAA72B3D2E Q37326072-D3116927-86A6-49EA-86CF-44A2CDB50975 Q37355506-9B333E54-C758-46AA-A443-D5A1B3DE3332 Q37432551-F4ACD054-881D-481F-97A7-8548E1372A48 Q37601854-20548F9D-F3E2-48E9-87DC-01125D18E8FF Q37687372-7586EF8F-6128-4759-8C3B-A028629D17DF

P2860

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

http://www.wikidata.org/entity/Q35720929

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

@ast

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

@en

type

label

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

@ast

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

@en

prefLabel

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

@ast

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

@en

P1433

Q35720929-108B3290-6C69-4340-8797-E9A74A2E9922

P1476

Q35720929-E0DCEAAC-0974-4BC2-B160-F4774F7D7D3C

P2093

Q35720929-031137D6-0653-442D-9917-FD02758712E3

Q35720929-17F9590B-0170-406D-B2EF-C2B773868579

Q35720929-2BDA4D9F-EDAC-4CD1-AB15-3C8DEFDC5708

Q35720929-2C1B90EF-B9CB-4DBD-9939-3F271E8C6383

Q35720929-2D096796-DC31-4260-9C13-D8D081C0FC3F

Q35720929-2F1C2D8E-5907-433E-8B2A-C9849B93CD9A

Q35720929-36FF67B7-BD6E-406C-AD64-C1C8EB2B74C3

Q35720929-3EC448A3-D8DD-4658-9D44-C4A0794D8A54

Q35720929-4BF2BF76-F55C-4A38-9727-221A20C9ECFF

Q35720929-68AA9763-294C-486B-9D15-60FAD1069CBD

P2860

Q35720929-0D1FF2A6-80C0-4441-86F5-03AB176218BF

Q35720929-1EFA2B3A-34F9-4593-AB5B-ED8ECD95EDE0

Q35720929-24C7F9F6-6D77-44B5-8C01-AB6D097859EC

Q35720929-2CCD9FE5-1640-4326-9062-11D25BE4D60A

Q35720929-40B1C79E-8FC4-4499-9FDD-3EE75F561BB8

Q35720929-477E7369-52B5-4B7E-83FB-058E347AA6CF

Q35720929-5042DB63-9DF4-4F61-B57D-F1B8AB1DF33E

Q35720929-505EF374-967D-4A31-9CEE-F83F32538046

Q35720929-54836787-2AA7-417C-82E8-6E082783458A

Q35720929-5DBF53A1-CD00-4366-9F14-5DECC4459F95

P304

Q35720929-7731489C-F8D9-49A7-8D7D-0ED9435D8EA9

P31

Q35720929-878C0B39-E148-41A7-A3EB-06C695BDEBCB

P356

Q35720929-59BC897B-E243-4692-BAF0-506FCF39F1D6

P407

Q35720929-F48230FE-4092-4E63-8FA3-FEE03FEDDD82

P433

Q35720929-9973FC26-F022-42A3-ABF2-F3434A898D56

P478

Q35720929-EE184E96-8107-4455-8B93-609D7C38697E

P577

Q35720929-D0CFEBCD-8766-4FDE-B5D8-4BEA48DB7057

P5875

Q35720929-34388B1F-B954-4863-A865-301E64253F5E

P698

Q35720929-15D8C9A0-D409-4BD2-AB87-3954CCE0029F

P932

Q35720929-1D644081-2C0F-4983-852A-E7DD17766AB9

P356

PNAS.0608113103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

@en

P2093

Amanullah Khan

http://www.w3.org/2001/XMLSchema#string

Barbara Haley

http://www.w3.org/2001/XMLSchema#string

Cynthia Osborne

http://www.w3.org/2001/XMLSchema#string

David Euhus

http://www.w3.org/2001/XMLSchema#string

Debu Tripathy

http://www.w3.org/2001/XMLSchema#string

Dorothee Herlyn

http://www.w3.org/2001/XMLSchema#string

Edward Clifford

http://www.w3.org/2001/XMLSchema#string

Eugene Frenkel

http://www.w3.org/2001/XMLSchema#string

Hossein Saboorian

http://www.w3.org/2001/XMLSchema#string

Jianqiang Wang

http://www.w3.org/2001/XMLSchema#string

P2860

HER-2 gene amplification can be acquired as breast cancer progresses

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.

Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.

The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.

Targeted therapy in breast cancer: the HER-2/neu gene and protein.

P304

17361-17365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0608113103

http://www.w3.org/2001/XMLSchema#string

P407

P433

46

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6718040

http://www.w3.org/2001/XMLSchema#string

P698

17079488

http://www.w3.org/2001/XMLSchema#string

P932

1838539

http://www.w3.org/2001/XMLSchema#string